{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:34:10Z","timestamp":1740126850644,"version":"3.37.3"},"reference-count":40,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background The therapy of severe manifestations of Graves\u02bc orbitopathy (GO) is still a challenge and requires good interdisciplinary cooperation. It is especially important to use stage-adapted anti-inflammatory therapy to avoid irreversible damage.<\/jats:p><jats:p>\n          Material and Methods Discussion of the latest results of multicentre randomised therapy studies on anti-inflammatory treatments for Graves\u02bc orbitopathy, as well as new therapeutic concepts.<\/jats:p><jats:p>\n          Results Mild cases of GO can be treated with only selenium supplementation and a watchful waiting strategy. In the moderate-to-severe active form of GO, primary therapy consists of i.\u200av. steroids (cumulative 4\u200a\u2013\u200a5\u2009g) in combination with orbital irradiation in patients with impaired motility. In patients with insufficient therapeutic response after 6 weeks, treatment should be switched to other immunosuppressive agents. In severe sight-threatening disease, bony orbital decompression is usually necessary. As basic research has improved our understanding of the underlying pathophysiology of GO, it has been possible to develop targeted therapies for GO. Teprotumumab, an IGF-1 receptor antibody, was effective in treating GO patients in a phase III trial and should soon be awarded approval for Europe.<\/jats:p><jats:p>\n          Conclusion The current therapy concept for Graves\u02bc orbitopathy is as follows: first anti-inflammatory therapy then surgical correction of the permanent defects. This may soon be modified, due to the use of targeted therapies.<\/jats:p>","DOI":"10.1055\/a-1328-2884","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T01:01:48Z","timestamp":1611795708000},"page":"24-32","source":"Crossref","is-referenced-by-count":5,"title":["Graves\u02bc Orbitopathy: Current Concepts for Medical Treatment"],"prefix":"10.1055","volume":"238","author":[{"given":"Michael","family":"Oeverhaus","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Essen, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mareile","family":"St\u00f6hr","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Essen, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"M\u00f6ller","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Essen, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0357-4192","authenticated-orcid":false,"given":"Dagmar","family":"F\u00fchrer","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Essen, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Eckstein","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Essen, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,1,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1055\/s-0035-1555762","article-title":"Current Insights into the Pathogenesis of Graves\u02bc Ophthalmopathy","volume":"47","author":"R S Bahn","year":"2015","journal-title":"Horm Metab Res"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/eje.1.02230","article-title":"Clinical assessment of patients with Graves\u02bc orbitopathy: the European Group on Graves\u02bc Orbitopathy recommendations to generalists, specialists and clinical researchers","volume":"155","author":"W M Wiersinga","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on Graves\u02bc Orbitopathy Guidelines for the Management of Graves\u02bc Orbitopathy","volume":"5","author":"L Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European Group on Graves\u02bc orbitopathy (EUGOGO) on management of GO","volume":"158","author":"L Bartalena","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/thy.2007.0315","article-title":"Consensus statement of the European group on Graves\u02bc orbitopathy (EUGOGO) on management of Graves\u02bc orbitopathy","volume":"18","author":"L Bartalena","year":"2008","journal-title":"Thyroid"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/cen.12222","article-title":"Smoking and thyroid","volume":"79","author":"W M Wiersinga","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/bjo.87.6.773","article-title":"Impact of smoking on the response to treatment of thyroid associated ophthalmopathy","volume":"87","author":"A Eckstein","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves\u02bc orbitopathy","volume":"364","author":"C Marcocci","year":"2011","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u02bc orbitopathy","volume":"90","author":"G J Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u02bc orbitopathy","volume":"97","author":"L Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1210\/jc.2013-3919","article-title":"A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with Graves\u02bc ophthalmopathy","volume":"99","author":"W Zhu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1055\/s-0043-116945","article-title":"Combination Therapy of Intravenous Steroids and Orbital Irradiation is More Effective Than Intravenous Steroids Alone in Patients with Graves\u02bc Orbitopathy","volume":"49","author":"M Oeverhaus","year":"2017","journal-title":"Horm Metab Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(00)02165-6","article-title":"Radiotherapy for Graves\u02bc orbitopathy: randomised placebo-controlled study","volume":"355","author":"M P Mourits","year":"2000","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00417-009-1214-3","article-title":"A retrospective study on the efficacy of total absorbed orbital doses of 12, 16 and 20\u2009Gy combined with systemic steroid treatment in patients with Graves\u02bc orbitopathy","volume":"248","author":"K T Johnson","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","article-title":"Clinical review: Intravenous glucocorticoids for Graves\u02bc orbitopathy: efficacy and morbidity","volume":"96","author":"S Zang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/bjophthalmol-2018-313697","article-title":"Treatment strategies for Graves\u02bc ophthalmopathy: a network meta-analysis","volume":"104","author":"X Zhou","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u02bc orbitopathy: a randomized controlled study","volume":"100","author":"M Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S2213-8587(18)30021-4","article-title":"Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2\u2009\u00d7\u20092 factorial, double-blind, randomised controlled trial","volume":"6","author":"R Rajendram","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u02bc orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","author":"G J Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves\u02bc orbitopathy","volume":"100","author":"M N Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2362.1986.tb01016.x","article-title":"Ciclosporin and prednisone v. prednisone in treatment of Graves\u02bc ophthalmopathy: a controlled, randomized and prospective study","volume":"16","author":"G Kahaly","year":"1986","journal-title":"Eur J Clin Invest"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3109\/02713683.2013.867355","article-title":"Intraocular pressure lowering effect of orbital decompression is related to increased venous outflow in Graves orbitopathy","volume":"39","author":"Z Onaran","year":"2014","journal-title":"Curr Eye Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/cen.13170","article-title":"Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves\u02bc orbitopathy","volume":"86","author":"X Ye","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u02bc orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"G J Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","article-title":"Treatment of active corticosteroid-resistant Graves\u02bc orbitopathy","volume":"30","author":"J V P\u00e9rez-Moreiras","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial","volume":"195","author":"J V Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.3390\/jcm9092816","article-title":"Anti-IL-6 Receptor Tocilizumab in Refractory Graves\u02bc Orbitopathy: National Multicenter Observational Study of 48 Patients","volume":"9","author":"L Sanchez-Bilbao","year":"2020","journal-title":"J Clin Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-316051","article-title":"Medical treatment in thyroid eye disease in 2020","author":"J J Khong","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jcjo.2017.07.009","article-title":"Role of methotrexate in thyroid-related orbitopathy","volume":"53","author":"A Rubinov","year":"2018","journal-title":"Can J Ophthalmol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/cen.13834","article-title":"Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a\u00a0step-down approach","volume":"89","author":"Z Sipkova","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1097\/IOP.0000000000001146","article-title":"Dysthyroid Optic Neuropathy","volume":"34 (4S Suppl.\u20091)","author":"P Saeed","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1210\/jc.2016-1279","article-title":"Hypoxia-Dependent HIF-1 Activation Impacts on Tissue Remodeling in Graves\u02bc Ophthalmopathy-Implications for Smoking","volume":"101","author":"G E G\u00f6rtz","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1097\/IOP.0000000000001147","article-title":"Phenotypes of Thyroid Eye Disease","volume":"34 (4S Suppl.\u20091)","author":"J M Uddin","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/thy.2013.0445","article-title":"Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy","volume":"24","author":"N Curro","year":"2014","journal-title":"Thyroid"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the Treatment of Active Thyroid Eye Disease","volume":"382","author":"R S Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for Thyroid-Associated Ophthalmopathy","volume":"376","author":"T J Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/thy.2019.0036","article-title":"Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves\u02bc Hyperthyroidism: A Phase I Study","volume":"29","author":"S HS Pearce","year":"2019","journal-title":"Thyroid"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.beem.2011.11.002","article-title":"Surgical treatment of Graves\u02bc ophthalmopathy","volume":"26","author":"A Eckstein","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1097\/IOP.0000000000001148","article-title":"Surgical Treatment of Diplopia in Graves Orbitopathy Patients","volume":"34 (4S Suppl.\u20091)","author":"A Eckstein","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1055\/s-0042-118040","article-title":"Endokrine Orbitopathie","volume":"233","author":"A Eckstein","year":"2016","journal-title":"Klin Monbl Augenheilkd"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1328-2884.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T22:59:24Z","timestamp":1628117964000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1328-2884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":40,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2021,1,27]]},"published-print":{"date-parts":[[2021,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1328-2884","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"type":"print","value":"0023-2165"},{"type":"electronic","value":"1439-3999"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}